Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1

Interventions

Cisplatin 45Radiotherapy 32Fluorouracil 27Paclitaxel 26Irinotecan 17Docetaxel 16Oxaliplatin 11Carboplatin 10pembrolizumab 9Cetuximab 8tislelizumab 7Surgical Procedures, Operative 7Neoadjuvant Therapy 7Drug Therapy 7Radiation 6Leucovorin 6sintilimab 5Nivolumab 5Immunohistochemistry 5Chemotherapy, Adjuvant 5Capecitabine 5nedaplatin 3durvalumab 3camrelizumab 3S 1 (combination) 3Magnetic Resonance Spectroscopy 3Gene Expression Profiling 3Gemcitabine 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Esophageal Squamous Cell Carcinoma × LGK974 × Clear all
NCT01351103 2025-06-13

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Novartis

Phase 1 Completed
185 enrolled
BreastDermatologicGastrointestinal

Esophageal Squamous Cell Carcinoma, Melanoma, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡